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The incidence of diabetes mellitus is rapidly increasing throughout the world. Although the exact cause of the disease is not fully clear,
perhaps, genetics, ethnic origin, obesity, age, and lifestyle are considered as few of many contributory factors for the disease
pathogenesis. In recent years, the disease progression is particularly linked with functional and taxonomic alterations in the
gastrointestinal tract microbiome. A change in microbial diversity, referred as microbial dysbiosis, alters the gut fermentation
profile and intestinal wall integrity and causes metabolic endotoxemia, low-grade inflammation, autoimmunity, and other affiliated
metabolic disorders. This article aims to summarize the role of the gut microbiome in the pathogenesis of diabetes. Additionally,
we summarize gut microbial dysbiosis in preclinical and clinical diabetes cases reported in literature in the recent years.
1. Introduction
The gastrointestinal tract (GIT) harbors a dense and diverse
microbial community, which includes archaea, bacteria,
protozoans, and viruses, and is commonly referred to as
microbiome. There are approximately 100 trillion bacteria that
occupy the GIT mucosal surface, constantly interacting with
metabolically and immunologically active cells. These
microbes not only act as the first line of defense against
foreign particles but also initiate a vast array of immunolog-
ical activities that augment mucosal and systemic immunity
[1]. The GIT microbiome displays very diverse physiological
features: digestion of complex carbohydrates, vitamins syn-
thesis, immune and inflammatory response modulation,
and hormones and neurotransmitter production [2]. The
much-emphasized gut-brain axis and gut-hypothalamus axis
are influenced by microbes through unknown methods/fac-
tors to regulate food intake, metabolism, and energy
homeostasis [3]. Through these neuronal and endocrine
axes, microbes can sense host metabolic status and alter
nutrient availability to meet the body needs. Brown and
Hazen [4] described the GIT microbiome as an endocrine
organ that translates nutritional cues into hormone-like sig-
nals to impact host physiology and diseases. Recently, there
have been several scientific reports that link the GIT micro-
biome with systemic diseases including obesity, diabetes,
hepatopathy, rheumatoid arthritis, cancer, and cardiovascu-
lar diseases [5–8].
Diabetes mellitus is an important metabolic disorder
of public health significance that results from a myriad
of factors. A recent survey suggests that approximately
422 million individuals around the globe suffer from dia-
betes and, by 2030, diabetes will be the 7th leading cause
of human death [9]. The current global prevalence rate of
diabetes is 8.5%, and the estimated death toll for direct
diabetes-caused morbidity for 2014 was 1.6 million [10].
Perhaps, the figure may get much higher if we also
include deaths caused by high blood glucose associated
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with other diseases. Over time, diabetes can lead to secondary
complications, such as cardiovascular disease, cerebrovas-
cular disease, neuropathy, retinopathy, nephropathy, and
limb amputation [10, 11]. Broadly, diabetes is categorized
among two common types, insulin-dependent type 1 diabe-
tes mellitus (T1DM) and insulin-independent type 2 diabetes
mellitus (T2DM). The less common types of diabetes include
gestational diabetes, monogenic diabetes (inherited form),
and cystic fibrosis-related diabetes. Among all of these types
of diabetes, the former two are the most discussed conditions
and have slightly different etiologies and pathogenesis, but
mainly common outcomes.
Genetics, nutrition, autoimmunity, and the environment
may be few of the many etiological factors that partially or
collectively contribute to the diabetes disease pathology.
Among the environmental factors, the GIT microbiome has
gained much interest, based in part on experimentation in
human diabetic subjects and nonobese diabetic (NOD) mice
or biobreed diabetes rodent models [12]. Studies with the
germ-free model of NOD mice reported enhanced suscepti-
bility to autoimmune and allergic diseases and spontaneous
development of diabetes [13]. In brief, accumulated evi-
dences suggest a prominent role of microbiome in diabetes,
autoimmunity, and other metabolic diseases. The present
article, therefore, is designed to delineate the significance of
GIT microbiome in the pathophysiology of diabetes and
how management of microbiome can relieve the patient.
2. Role of GIT Microbiome in Host
Metabolism and Energy Homeostasis
Hosts and their microbiomes develop symbiotic relation-
ships through interactive evolutionary processes that mutu-
ally benefit both. In a broader sense, the resident symbionts
regulate host metabolism in multiple ways, integrating phys-
iological homeostasis, immune-inflammatory signaling, and
energy compliance. Multiple mechanisms are thought to link
microbial activity in the GIT and the systemic metabolism.
Carbohydrates are the primary sources of energy for both
the human host and their microbes. Conventionally reared
rodents have higher carbohydrate metabolites from glycoly-
sis and tricarboxylic acid cycle compared to germ-free rodent
models demonstrating that conventionally reared rodents
have a higher energy-harvesting capability [14]. Humans lack
enzymes for digestion of complex carbohydrates, including
cellulose, resistant starch, xylans, and inulin. In contrast,
the microbiome encodes enzymes required for indigested
carbohydrate fermentation. Microbial fermentation harvests
energy for microbial growth and generates monosaccharides
and short-chain fatty acids (SCFAs). The SCFAs act as
ligands for the G protein-coupled receptors GPR41 and
GPR43, expressed by enteroendocrine cells in the GIT
mucosa (Figure 1) [15–17]. Hooper et al. [18] observed that
colonization of germ-free rodents with GIT microbes
obtained from conventional rodents induced sodium/glucose
cotransporter-1 expression in epithelial enterocytes. Specifi-
cally, inoculation of Bacteroides thetaiotaomicron in humans
and mice promoted expression of genes involved in nutrient
absorption, mucosal barrier integrity, angiogenesis, and
xenobiotic metabolism [18, 19].
Short-chain fatty acids have significant effects on the GIT
wall health as, for example, a source of energy, anti-
inflammation agents, angiogenics and vasodilators, promoti-
lity agents, and wound healing agents [20]. Microbial
fermentation products also affect the muscles, liver, brain,
and adipose tissue metabolism. The liver metabolic profile
of gnotobiotic mice is different from that of conventionally
raised mice, probably because of an over influx of SCFAs into
the liver. Both hepatocytes and enterocytes are reported as
energy deprived and have an overexpression of AMP-
activated protein kinase (AMPK), which determines cellular
energy status in gnotobiotic germ-free mice [21, 22]. Butyrate
is principally used as an energy source for enterocytes,
whereas acetate and propionate are flushed to the liver
for lipogenesis and gluconeogenesis. Butyrate supplemen-
tation to obese, prediabetic mice significantly improved
the intestinal epithelial barrier and insulin secretion from
beta cells and decreased body adiposity as well as weight
gain, insulin resistance, hyperinsulinemia, and hyperglyce-
mia [23]. Everard et al. [24] reported that prebiotic, func-
tional foods that alter the microbiome fermentation profile
improve energy balance and leptin sensitivity by modulat-
ing enteroendocrine cell secretions in obesity and diabetic
mice models. Moreover, prebiotic supplementation reduces
hunger, increases satiety, and decreases total energy intake
by about 10% [25]. In the last few decades, Lactobacillus
has gained much importance as probiotic, live microbes
that augment the microbial profile. Li et al. [26] found that
Lactobacillus supplementation improved insulin homeostasis
accompanied by glucose tolerance and protection of beta cell
islets in diabetic mice.
Notably, certain bacterial clades, for example, Bacteroi-
detes and Firmicutes, enhance ATP-binding cassette trans-
porter expression in enterocytes and glucagon-like peptide
1 and 2 secretion. Everard et al. [24] observed a positive
correlation between genus Anaerotruncus abundance in
the GIT and gut permeability, glucose intolerance, blood
triglyceride content, and muscle lipid concentrations.
Similarly, family Desulfovibrionaceae is associated with
dyslipidemia and obesity [27]. In a broader sense, a
microbiome shift, delineated by a rise in Firmicutes and
a decline in Bacteroidetes populations, is implicated in
obesity. The underlying mechanisms for these interactions
are not yet fully understood. Although the aforementioned
literature enhances our understanding of the role of the
microbiome in host metabolism and energy homeostasis,
the identification of better molecular markers of metabolism
regulation is of greater significance.
3. GIT Microbiome and Metabolic Disorders as
Precursors to Diabetes
The gastrointestinal tract microbiome interacts with host
nutrition, the environment, and host genetics for the
development of obesity-related metabolic disorders. Various
studies have reported that GIT microbial dysbiosis enhances
energy harvest and expression of obese phenotype. High
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throughput amplicon sequencing of the 16S rRNA gene
reveals that a change in the Bacteroidetes/Firmicutes ratio
is associated with higher expression of microbial genes
that encode enzymes related to carbohydrate metabolism.
The microbiomes of obese persons differ from those of
lean individuals and, generally, are characterized by a
lower prevalence of phylum Bacteroidetes and a higher
prevalence of phylum Firmicutes [28]. Therefore, changes
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Figure 1: Change in the microbiome fermentation profile changes gut permeability and energy homeostasis which causes endotoxemia,
low-grade inflammation, and obesity. Poor energy homeostasis leads to hyperglycemia and hyperlipidemia which may lead to obesity and
ultimately insulin resistance.
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in the Bacteroidetes/Firmicutes ratio portray an environ-
mental factor that provides genetic material for increased
capacity to harvest energy from the diet [29]. The higher
energy harvest promotes lipogenesis and increases the num-
ber and size of lipid droplets in the extraintestinal tissues
(Figure 2). Most patients suffering from this metabolic
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Figure 2: A schematic diagram describing the role of the gastrointestinal tract microbiome in the development of the metabolic syndrome
that leads to diabetes mellitus pathogenesis. Microbial dysbiosis impairs intestinal wall integrity and allows translocation of toxins from
the gut lumen to the systemic circulation. This endotoxemia leads to low-grade inflammation, autoimmunity, and oxidative stress that
may lead to beta cell destruction or insulin resistance.
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syndrome have excessive fat accumulation which suggests
that the dyslipidemia is an important etiological factor of
the syndrome [30].
Autoimmunity, insulin resistance, and hypertension are
a few potentially lethal consequences of obesity. Transient
changes in the microbiome can disrupt the microbiome
and host-immune axis. There is an increasing amount of
evidence that suggests that intestinal commensals directly
influence the development of autoimmunity and low-
grade inflammation [31]. In general, the inadequately
functional immune system of gnotobiotic mice or neonates
suggests that its maturation is compelled by the resident
microbiome. However, cellular and molecular processes
by which GIT microbes promote autoimmune responses
are poorly understood. Different studies propose more
than one method of immune disruption in systemic and
local immune systems in response to changes in microbial
ecology. Candidatus savagella, a normal commensal bacte-
rium, is associated with the development of autoimmune
arthritis and encephalomyelitis. In contrast, the same bacte-
rium is involved in protection against autoimmune T1DM
[32]. In the previously mentioned experiments, excessive
production of T helper 17 (Th-17) by Candidatus savagella
has a causal role in autoimmune diseases. In other studies,
commensal Bacteroides fragilis has been associated with sys-
temic Th1 cells and local interleukin-10- (IL-10-) producing
regulatory T cells [33]. The microbe can prevent autoim-
mune encephalomyelitis in mice via conversion of naïve
CD4+ T cells into IL-10-producing regulatory T cells [32].
In addition, SCFAs, through G protein-coupled receptors,
have been associated with inflammatory bowel disease,
colitis, arthritis, diabetes, and asthma [34].
Microbiome-triggered chronic low-grade inflammation
is another important causal factor for obesity and related
metabolic syndromes. Cani et al. [35] found that metabolic
endotoxemia, caused by extraintestinal lipopolysaccharides
(LPS) infiltration, causes inflammation, oxidative stress, obe-
sity, and diabetes. Resident Gram-negative bacteria secrete
LPS and other endotoxins in the GIT. These endotoxins
can cross the GIT mucosal barrier through mucosal tight
junctions or by infiltrating chylomicrons [36]. Once in the
extraintestinal tissue, endotoxins trigger innate immune
responses by activating CD14, nucleotide oligomerization
domain (NOD), and toll-like receptor 4 (TLR4) at the surface
of dendritic cells and macrophages. Furthermore, recent
studies suggest activation of innate immune system by
recruitment of effector molecules (inflammasomes, peptido-
glycans, TNF-α, IL-1β, and flagellin) in response to LPS infil-
tration [37]. In brief, microbial dysbiosis, caused by high-fat
diet supplementation, can increase intestinal permeability,
LPS infiltration, oxidative stress, macrophage infiltration,
and adipose tissue inflammation [35].
4. Type 1 Diabetes Mellitus
Type 1 diabetes is characterized by a lack of sufficient insulin
production and elevated blood glucose levels. The disease
mostly occurs in children and young adults and, therefore,
is also called juvenile diabetes. The disease is usually caused
by oxidative and/or T cell-mediated autoimmune destruction
of pancreatic beta cells, leading to partial or complete loss of
insulin production [38, 39]. The specific environmental con-
stituents eliciting beta cell autoimmune destruction are not
fully known. It is thought that in hereditarily prone persons,
a chronic inflammatory disease of the GIT elicits the primary
offense, leading to autoimmune destruction of β-islet cells
[40]. Recent research has highlighted the role of the GIT
microbiome in the development of T1DM and that the
disease is associated with unidentified GIT microbiome
dysbiosis [41]. Brown et al. [42] found a higher proportion
of Actinobacteria, Bacteroidetes, and Proteobacteria phyla
in TIDM subjects, whereas, the control group had higher
abundance of Firmicutes, Fusobacteria, Tenericutes, and
Verrucomicrobia. A longitudinal study on young children
suggested that bacterial diversity diminishes over time in
genetically prone autoimmune children when compared
with healthy control age-mates. Particularly, it was
observed that Bacteroides ovatus contributed almost 24%
of constituents in the phylum Bacteroidetes in the T1DM
subjects [43]. Results from other studies [44–46] have also
shown changes in the microbial ecology and a decline in
bacterial diversity in T1DM cases. However, there is still
a scarcity of scientific literature that connects such alterations
in the microbiome as a predictor of its functional role in the
disease pathology (Table 1).
The available literature suggests that there might be more
than one coincident or independent pathogenesis route
through which the GIT microbiome can lead to beta cell
destruction and the onset of T1DM. In the first concept, as
mentioned above, microbiome dysbiosis-associated immune
regulation may lead to T cell-mediated destruction of beta
cells in genetically susceptible individuals [35, 47]. The second
proposed pathogenesis correlates T1DM with gut leakiness,
endotoxemia, and immune-deregulation-associated chronic
low-grade inflammation [1, 36]. Some bacterial species, such
as Akkermansia muciniphila, Bacteroidetes thetaiotaomicron,
and E. coli, enhance gut permeability and endotoxemia
which may lead to metabolic syndrome [48].
Through earlier experiments, it is widely recognized that
oxidative stress plays a major role in the development of dia-
betes. A comparatively less-discussed notion is themetabolic-
related oxidative stress under microbial dysbiosis. Morgan
et al. [49] observed microbial dysbiosis and disrupted nutri-
ent availability during metabolic syndromes associated with
major changes in oxidative stress pathways. Furthermore,
supplementation of Lactobacillus-based probiotic yogurt has
been shown to suppress streptozotocin-induced diabetogenic
state and to improve antioxidant status [50].
It is still uncertain if these microbiome-triggered
oxidative stress, autoimmunity, or inflammatory abuses
of beta cells act independently or work together. Perhaps,
underlining mechanisms have interrelated pathways and
common output.
5. Type 2 Diabetes Mellitus
Hyperglycemia associated with progressive resistance to insu-
lin action and inappropriate insulin secretion is characterized
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as T2DM. The disease usually develops in genetically suscep-
tible adults due to a sedentary lifestyle and represents as
much as 90% of all the cases of diabetes. Over the past few
decades, the disease incidence has increased tremendously
along with an early age onset. The etiology and pathogenesis
of the T2DM are a very complex assembly of genetic and epi-
genetic elements influenced by a complex societal framework
and environmental factors. Among the environmental
factors of T2DM, GIT microbiome assessment and charac-
terization have attracted major research interest in the recent
years. Metformin is the most commonly used medication for
controlling hyperglycemia in T2DM patients. The exact
mode of action of this drug is not well defined, though it
has been shown that the drug improves gut microbial diver-
sity, metalloproteins-encoding gene expression in gut bacte-
rial species, and glycemic index [51].
Table 1: Summary of the gut microbiome and metagenomic changes observed in different preclinical and clinical diabetes studies.
Study format Clinical features/major findings Microbiome changes
Metagenome/metabolome
changes
Reference
Longitudinal
infant T1DM
Out of 33 genetically predisposed
T1DM infants, 12% developed
T1DM, whereas 21% developed
T1DM autoantibodies during the
first 4 years of life
A decrease in alpha diversity
and an overabundance of
Blautia and Rikenellaceae
Modulation of sphingomyelin,
lithocholic acid, lipids,
branch-chained amino acid
concentrations, and sugar
transport pathways
[55]
Longitudinal
infant T1DM
All four enrolled infants
developed autoimmunity and
T1DM within the first 3 years
Drop in alpha diversity and
increase in Bacteroidetes
(Bacteroides spp.) and
decrease in Firmicutes
Not applicable [43]
Metagenomics of
the microbiome
in T1DM patients
Microbial fermentation and
functional components
promoted autoimmune
destruction of beta cells
Higher Bacteroides and lower
Prevotella abundance
T1DM patients had higher
carbohydrate metabolism,
adhesions, motility, phages,
prophages, sulfur metabolism,
and stress responses
[42]
Metagenomics of
the microbiome
in T2DM patients
microbiome
Not applicable
Microbial dysbiosis characterized by
a decrease in butyrate-producing
bacteria and an increase in the
populations of various
opportunistic pathogens
Higher gut oxidative stress
and membrane transport
of sugars
[46]
Metagenome in
T2DM women
Elevated glucose, C peptide,
leptin, triglycerides, and
oxidative stress
Enriched with Lactobacillus sp.
and depletion of Clostridium sp.
Higher sugar metabolism and
transport, fatty acid synthesis,
and oxidative stress pathways
[58]
Adult T2DM
Ratio of Bacteroidetes to
Firmicutes correlated positively
and significantly with plasma
glucose concentrations
Higher alpha diversity. Changes in
beta diversity were characterized by
higher Bacteroidetes in T2DM cases
and Firmicutes belonging to class
Clostridia in controls subjects
Not applicable [44]
Metagenomics of
T2DM patients
before and after
bariatric surgery
Surgery improved BMI,
hypertension, lipid profile,
and glycemic index
Bacteroidetes/Firmicutes ratio
increased. Several changes in
taxonomy composition
Changes in carbohydrate
metabolism and the
phosphotransferase system
[59]
Antibiotic
treatment in
high-fat
diet-induced
diabetic mice
Antibiotic treatment reduced
endotoxemia, glucose
intolerance, body weight
gain, inflammation, and
oxidative stress
Antibiotic treatment changes
microbiome architecture of
high-fat diet-induced diabetic mice
Drop in endotoxemia, tissue
inflammation, and oxidative
stress markers
[35]
Fecal transplant
from healthy
mice to T1DM
genetically
susceptible mice
Prevents autoimmunity,
and insulitis and delays
T1DM development
Increase in Bacteroidetes and
decrease in Firmicutes and
Clostridiaceae and Lactobacillaceae
abundance
Increase in IgA, TGFβ
concentrations, and CD8+,
CD103+, and CD8αβ T cells
[60]
Antibiotic
treatment of
biobred
diabetes-prone
rat
Antibiotic treatment
delayed/protected against
TIDM
Antibiotic treatment lowered
Bacteroides spp.
Antibiotic treatment
lowered insulitis
[12]
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The gut microbiome interacts with host genetics and
encodes several essential proteins required for human health
and disease [52]. Xu and Gordon [53] suggested that
microbes can modify gene expression in the host to create
physiological homeostasis or to elicit certain disease patho-
genesis. Particularly, microbiome-triggered changes in intes-
tine tight-junction proteins and alkaline phosphatase activity
in the gut milieus may increase gut permeability and lead
to the pathogenesis of insulin resistance [54]. In obese
individuals, T2DM pathogenesis is linked to activation of
inflammatory pathways that cause insulin resistance through
activation of the IκB kinase complex, protein kinases 1 and 2,
and c-Jun N-terminal kinases (JNKs) in the tissues [55]. In
brief, the predominant notion of T2DM pathogenesis incor-
porates a nexus of microbial dysbiosis, gut leakiness, autoim-
munity, chronic inflammation of adipose tissue, obesity, and
insulin resistance [56].
Microbial dysbiosis associated with T2DM is charac-
terized by poor species richness and diversity (Table 1). Quite
a few studies reported changes in the abundance of certain
bacterial clades in diabetic conditions, such as a change in
the Firmicutes/Bacteroidetes ratio [44]. Correction of
microbial dysbiosis by supplementation with prebiotics, as
reported by Cani et al. [36], improved Bifidobacterium abun-
dance which is significantly and positively correlated with
improved glucose tolerance and inflammation in prebiotic-
treated mice. Similarly, Wu et al. [57] also reported a higher
abundance of Bifidobacterium in healthy subjects when
compared with T2DM patients. Furthermore, a T2DM
metagenome study revealed an enrichment of sulphate
reduction and oxidative stress resistance functions and a
decline in some butyrate-producing bacteria in T2DM
patients [46]. Short-chain fatty acids produced during micro-
bial fermentation, particularly butyrates, enhance gut wall
integrity and prevent metabolic endotoxemia, inflammation,
and associated disorders.
Currently, there is very little published work that
characterizes the microbiome and metagenomics of diabetes.
Additionally, the published literature shows contradictions
in taxonomic affiliations of the microbiome with diabetes.
Furthermore, most of the published work explored only
phylogenetic characteristics of the diabetes microbiome and
pays far less attention to the functional contents of the micro-
biome. Perhaps, based on the available literature, it can be
concluded that changes in the microbiome may have sub-
stantial effects on host metabolism [29]. Any significant
change in bacterial diversity may affect the gut fermentation
profile, gut wall permeability, and mucosal and systemic
immunity and, therefore, may trigger mechanisms responsi-
ble for oxidative stress, endotoxemia, obesity, and hypergly-
cemia [5]. While many reports have shown changes in the
ratio of the predominant phyla in the gut, the question
remains as to the functional effects of such constituents and
if this are clinically significant.
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